For instance, the combination therapy of DKY709 and PDR001 (a humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2) is being tested in patients with triple-negative breast cancer in an ongoing phase I trial (NCT03891953). This evidence concerns the gene PDCD1LG2 and triple-negative breast carcinoma.